Literature DB >> 1656687

Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells.

F F Johansen1, N H Diemer.   

Abstract

Increased excitation may be involved in the development of delayed CA1 pyramidal cell death in hippocampus after global cerebral ischemia. Therefore we investigated the possible neuroprotective effect of the GABA uptake inhibitor, R-(-)-1-(4,4-(3-methyl-2-thienyl)-3-butenyl)-3-piperidine carboxylic acid (No-328), in a rat cerebral ischemia model of delayed CA1 pyramidal cell death. No-328 in doses of 36 mg/kg given 30 min before, and 1, 24, 48 and 72 h after ischemia significantly reduced the CA1 neuron loss. Doses of 50 mg/kg of No-328 given immediately before, 24 h and 48 h after ischemia, also reduced the CA1 neuron loss significantly. Furthermore, we demonstrated that postischemic treatment with diazepam (4 x 15 mg/kg) significantly reduced the CA1 neuron loss. However, postischemic treatment with several doses (5 x 12 mg/kg) of the GABA analog, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP), offered no CA1 neuron protection when given alone, but when administrated together with diazepam (4 x 15 mg/kg) it significantly reduced the CA1 neuron loss. We conclude that enhancement of postischemic GABA neurotransmission, during the first 2-3 days after ischemia, may reduce the ischemic CA1 damage through a continuous increase in hippocampal GABA extracellular levels (No-328), or through an increase in sensitivity to GABA neurotransmission (diazepam).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656687     DOI: 10.1111/j.1600-0404.1991.tb04893.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  13 in total

1.  Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions.

Authors:  P Saransaari; S S Oja
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

2.  Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.

Authors:  Ken Madden; Wayne Clark; Nicola Lessov
Journal:  Clin Med Res       Date:  2003-04

3.  Glutamate receptor activation induces carrier mediated release of endogenous GABA from rat striatal slices.

Authors:  J Wang; G Lonart; K M Johnson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.

Authors:  J C Adkins; S Noble
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 5.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

6.  Inhibition in postischemic rat hippocampus: GABA receptors, GABA release, and inhibitory postsynaptic potentials.

Authors:  F F Johansen; T Christensen; M S Jensen; E Valente; C V Jensen; T Nathan; J D Lambert; N H Diemer
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

7.  A sequential impairment of cortical astrocytes and GABAergic neurons during ischemia is improved by mGluR₁,₅ activation.

Authors:  Zhan Liu; Wei Huo; Wei Sun; Manhua Lv; Fang Li; Zhiqiang Su
Journal:  Neurol Sci       Date:  2012-10-31       Impact factor: 3.307

8.  Inhibitory effects of excitatory amino acids on pyramidal cells of the in vitro turtle medial cortex.

Authors:  R E Russo; J C Velluti
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

9.  Afferents to the seizure-sensitive neurons in layer III of the medial entorhinal area: a tracing study in the rat.

Authors:  T Eid; B Jorritsma-Byham; R Schwarcz; M P Witter
Journal:  Exp Brain Res       Date:  1996-05       Impact factor: 1.972

10.  Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids.

Authors:  P J Hutchinson; M T O'Connell; P G Al-Rawi; C R Kett-White; A K Gupta; L B Maskell; J D Pickard; P J Kirkpatrick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.